Qiufang Liu
Overview
Explore the profile of Qiufang Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zuo Y, Liu Q, Li N, Li P, Fang Y, Bian L, et al.
J Cancer Res Clin Oncol
. 2024 Oct;
150(10):469.
PMID: 39436414
Purpose: To establish an explainable F-FDG PET/CT-derived prediction model to identify EGFR mutation status and subtypes (EGFR wild, EGFR-E19, and EGFR-E21) in lung adenocarcinoma (LUAD). Methods: Baseline F-FDG PET/CT images...
2.
Liu Q, Xu X, Yang Z, Zhang J, Li J, Qiao Y, et al.
J Nucl Med
. 2024 Oct;
65(11):1695-1701.
PMID: 39389628
In several malignancies, only a limited number of patients respond to immune checkpoint inhibitors. Predicting and monitoring responses to these inhibitors represent an unmet clinical need. Here, we developed a...
3.
Liu X, Guo T, Huang Z, Chen S, Chen L, Li C, et al.
J Mater Chem B
. 2024 Oct;
12(43):11218-11229.
PMID: 39373076
Background: radiation-induced skin injury (RISI) is a common complication of radiotherapy, affecting 85-95% of patients. Current treatments lack sufficient evidence of efficacy. Acellular dermal matrix (ADM) hydrogels have shown promise...
4.
Zhang L, Liu Q, Liu Y, Ye B, Hu C, Li X, et al.
Acta Biochim Biophys Sin (Shanghai)
. 2024 Sep;
PMID: 39238440
No abstract available.
5.
Huang W, Pang Y, Liu Q, Liang C, An S, Wu Q, et al.
Research (Wash D C)
. 2024 May;
6:0282.
PMID: 38706713
Fibroblast activation protein (FAP) is among the most popular targets in nuclear medicine imaging and cancer theranostics. Several small-molecule moieties (FAPI-04, FAPI-46, etc.) are used for developing FAP-targeted theranostic agents....
6.
Lu X, Liu Q, Yan G, Wang X, Liu X, Tian Q, et al.
J Mater Chem B
. 2024 May;
12(21):5207-5219.
PMID: 38693796
Transarterial chemoembolization (TACE) is widely recognized as a non-surgical treatment approach for advanced liver cancer, combining chemotherapy with the blockage of blood vessels supplying the tumor. To enhance the efficacy...
7.
Zhang Y, Cao M, Wu Y, Malih S, Xu D, Yang E, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38580333
Background: The programmed cell death protein-1 (PD-1)/programmed death receptor ligand 1 (PD-L1) axis critically facilitates cancer cells' immune evasion. Antibody therapeutics targeting the PD-1/PD-L1 axis have shown remarkable efficacy in...
8.
Zhu H, Hao S, Tseng I, Shen J, Rivin Del Campo E, Davies A, et al.
Quant Imaging Med Surg
. 2023 Sep;
13(9):6280-6295.
PMID: 37711778
Background: Among cancers, esophageal cancer (EC) has one of the highest incidences and mortality in Asia. As recognized in many national guidelines, functional imaging performed with position emission tomography is...
9.
Zuo Y, Liu Q, Li N, Li P, Zhang J, Song S
Front Oncol
. 2023 May;
13:1173355.
PMID: 37223682
Purpose: To develop and interpret optimal predictive models to identify epidermal growth factor receptor (EGFR) mutation status and subtypes in patients with lung adenocarcinoma based on multicentric F-FDG PET/CT data,...
10.
Zhang Y, Zhang D, An S, Liu Q, Liang C, Li J, et al.
Research (Wash D C)
. 2023 Mar;
6:0077.
PMID: 36939440
Overexpression of CD47 is frequently observed in various types of human malignancies, inhibiting myeloid-mediated elimination of tumor cells and affecting the prognosis of cancer patients. By mapping biomarker expression, immuno-positron...